Subscribe to RSS
DOI: 10.1055/s-0040-1712971
2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
Publication History
Publication Date:
11 June 2020 (online)
![](https://www.thieme-connect.de/media/sth/202004/lookinside/thumbnails/10-1055-s-0040-1712971_02760-1.jpg)
Welcome to the latest of our Eberhard F. Mammen Award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis & Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2020 represents over 10 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:
-
Most popular article awards: Awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor-in-Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “open access” status for these articles thereafter.
-
Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US$1,000 are awarded in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. In general, previous award winners are excluded from the second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying those reviews or papers, and then excluding those with potential conflicts from voting.
![](https://www.thieme-connect.de/media/sth/202004/thumbnails/10-1055-s-0040-1712971-i02760-1.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
Further details of the awards and the award winners are posted online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and previous award winner announcements are also available in print ([Table 1]). This includes the recent announcement of the 2019 Young Investigator Awards.
It is therefore with great pleasure that we would like to announce the latest winners of the 2020 Eberhard F. Mammen Awards for the most popular articles from STH for the period of 2018 to 2019 inclusive.
-
References
- 1 Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018; 44 (08) 780-786
- 2 Schreiber K, Breen K, Cohen H. , et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017; 43 (06) 562-571
- 3 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
- 4 Gosselin RC, Adcock D, Dorgalaleh A. , et al. International council for standardization in haematology recommendations for hemostasis critical values, tests, and reporting. Semin Thromb Hemost 2020; 46 (04) 398-409
- 5 Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008; 34 (08) 779-793
- 6 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
- 7 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (02) 189-203
- 8 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (08) 865-883
- 9 Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. Semin Thromb Hemost 2019; 45 (02) 157-163
- 10 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019; 45 (05) 433-448
- 11 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost 2016; 42 (05) 526-532
- 12 Elewa H, Ahmed D, Barnes GD. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting: searching for the best combination. Semin Thromb Hemost 2016; 42 (06) 662-670
- 13 Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. Semin Thromb Hemost 2013; 39 (03) 291-305
- 14 Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the New Roche Cobas t 711 fully automated coagulation analyzer. Semin Thromb Hemost 2019; 45 (03) 308-314
- 15 Schulman S. Update on the treatment of venous thromboembolism. Semin Thromb Hemost 2016; 42 (08) 891-898
- 16 Raskob GE, Angchaisuksiri P, Blanco AN. , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost 2014; 40 (07) 724-735
- 17 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2014; 40 (03) 277-283
- 18 Batorova A, Jankovicova D, Morongova A. , et al. Inhibitors in severe hemophilia a: 25-year experience in Slovakia. Semin Thromb Hemost 2016; 42 (05) 550-562
- 19 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
- 20 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
- 21 Tersteeg C, Fijnheer R, Pasterkamp G. , et al. Keeping von Willebrand Factor under control: alternatives for ADAMTS13. Semin Thromb Hemost 2016; 42 (01) 9-17
- 22 Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 2015; 41 (02) 228-236
- 23 van der Vorm LN, Huskens D, Kicken CH. , et al. Effects of repeated bouts of exercise on the hemostatic system. Semin Thromb Hemost 2018; 44 (08) 710-722
- 24 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34 (08) 772-778
- 25 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost 2014; 40 (01) 121-128
- 26 Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45 (07) 661-673
- 27 Russo V, Attena E, Mazzone C. , et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018; 44 (04) 364-369
- 28 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (05) 579-589
- 29 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23 (04) 349-356
- 30 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost 2003; 29 (05) 435-450
- 31 Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost 2017; 43 (04) 386-396
- 32 Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and expert opinion. Semin Thromb Hemost 2016; 42 (07) 717-723
- 33 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40 (05) 571-576
- 34 Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017; 43 (08) 849-863
- 35 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 2017; 43 (03) 253-260
- 36 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
- 37 McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost 2015; 41 (03) 300-314
- 38 Maclachlan KH, Stevens HP, Tran HA, Chunilal SD. Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with no increase in major bleeding. Semin Thromb Hemost 2019; 45 (01) 94-99
- 39 Cohen H, Efthymiou M, Gates C, Isenberg D. Direct oral anticoagulants for thromboprophylaxis in patients with antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 427-438
- 40 Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 2017; 43 (03) 270-276
- 41 Radulescu VC. Anticoagulation therapy in children. Semin Thromb Hemost 2017; 43 (08) 877-885
- 42 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 01) 3-15
- 43 Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test?. Semin Thromb Hemost 2019; 45 (01) 50-60
- 44 Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost 2013; 39 (03) 283-290
- 45 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013; 39 (03) 258-266
- 46 Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb Hemost 2018; 44 (05) 445-452
- 47 Marlar RA, Gausman JN, Engel JW. Validation of hemostasis and coagulation assays: recommendations and guidelines. Semin Thromb Hemost 2014; 40 (02) 186-194
- 48 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
- 49 Anker-Møller T, Troldborg A, Sunde N, Hvas AM. Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review. Semin Thromb Hemost 2017; 43 (07) 750-758
- 50 Lippi G, Franchini M, Favaloro EJ. Diagnostics of inherited bleeding disorders of secondary hemostasis: an easy guide for routine clinical laboratories. Semin Thromb Hemost 2016; 42 (05) 471-477
- 51 Favaloro EJ, Lippi G. Editorial compilation VI. Semin Thromb Hemost 2019; 45 (01) 5-9
- 52 Schulman S. Recent advances in thrombosis and hemostasis-part IV. Semin Thromb Hemost 2019; 45 (02) 130-131
- 53 Kwaan HC, Teruya J. Perturbation of hemostatic function by nonbiologic surfaces. Semin Thromb Hemost 2018; 44 (01) 5-6
- 54 Adcock DM, Gosselin RC. Laboratory assessment of hemostatic and anticoagulant therapy. Semin Thromb Hemost 2017; 43 (03) 242-244
- 55 Schulman S, Islam MS. Recent advances in thrombosis and hemostasis-part II. Semin Thromb Hemost 2017; 43 (08) 809-810
- 56 Lisman T, de Moerloose P. The role of fibrinogen and factor XIII in hemostasis, and the identification and treatment of associated disorders. Semin Thromb Hemost 2016; 42 (04) 331-332
- 57 Othman M, McLintock C, Kadir R. Thrombosis and hemostasis related issues in women and pregnancy. Semin Thromb Hemost 2016; 42 (07) 693-695
- 58 Favaloro EJA. 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 59 International Council for Standardization in Haematology (ICSH) website. Available at: https://icsh.org/ . Accessed January 26, 2020